Cimon Medical exists to innovate life saving solutions. We do this by developing and manufacturing Doppler ultrasound technology for health care facilities. Our first product, NeoDoppler, provides non-invasive continuous blood flow monitoring for infants.
To reduce neonatal mortality and the risk of neurodevelopmental damage, there is a strong need for improved monitoring of brain circulation during birth, resuscitation and intensive care treatment. But no adequate solution has been available – until now.
Our technology originates from the world-renowned ultrasound environment at The Norwegian University of Science and Technology (NTNU) and St. Olavs University Hospital, in Trondheim, Norway.
Here it was invented by Professor Hans Torp and Pediatric Cardiologist Siri Ann Nyrnes, who are both driving forces in the local ultrasound community.
Doppler Ultrasound for clinical use is developed at the internationally renowned Department of Circulation and Imaging at the Norwegian Technical University (NTNU) in Trondheim, Norway
Pilot- and clinical studies with prototypes initiated at St.Olavs and Oslo Univ. Hospital
Launch of 1st regulatory approved product – NeoDoppler
Idea and concept for Cimon technology developed by Prof. Hans Torp
Industrialization process with selected manufacturing partners
St.Olavs Hospital collaborates closely with NTNU on education and has a special responsibility for sharing knowledge and supporting professional development in the specialist health services in central Norway.
The regional hospital is responsible for the most specialized treatment services, and therefore has patients throughout central Norway. St. Olavs Hospital also has some national functions and collaborates with other university hospitals.
NTNU is Norway’s university for higher ed- ucation in technology and natural sciences.
NTNU has 9 faculties and 55 institutes and more than 100 laboratories. The university employs approximately 5360 academic staff and has 40 000 students.
The university is recognized for a broad cooperation with national and international businesses and has an annual budget of approx. 9 billion Norwegian kroner.
NTNU Technology Transfer AS works to create value from research based ideas that come out of The Norwegian University of Science and Technology (NTNU) and The Central Norway Regional Health Authority (Helse Midt-Norge).
NTNU Technology Transfers goal is to create benefit to society from these ideas in the form of new products, new services, new industries and new jobs.
